Market revenue in 2023 | USD 233.1 million |
Market revenue in 2030 | USD 337.3 million |
Growth rate | 5.4% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.87% in 2023. Horizon Databook has segmented the UK attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
ADHD in the UK is underdiagnosed and undertreated. Growing prevalence of ADHD among children and increased efforts to spread awareness & provide diagnosis and treatment are expected to propel the market growth. For example, the UK Adult ADHD Network (UKAAN) provides research & training for mental health professionals, cost-effective services, and education to increase awareness of ADHD.
Furthermore, shortage of medications for ADHD is causing significant challenges for millions of UK individuals who rely on these drugs. Currently, shortages are impacting four of the five licensed types of ADHD medication in the country. This disruption is affecting the mental health & wellbeing of those affected and hindering their daily lives.
Currently, shortages are impacting four of the five licensed types of ADHD medication in the country. This disruption is affecting the mental health & wellbeing of those affected and hindering their daily lives. The shortage is primarily attributed to manufacturing issues and a surge in global demand for ADHD medications.
Horizon Databook provides a detailed overview of country-level data and insights on the UK attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into UK attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account